CS1 SIR-T

CS1 SIR-T is an investigational cell therapy being developed by Angeles Therapeutics for the treatment of multiple myeloma. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR) technology to engineer T-cells that target CS1 (also known as SLAMF7), a cell surface protein highly expressed on malignant plasma cells. Unlike traditional Chimeric Antigen Receptor (CAR) T-cells, SIR-T cells are designed to mimic the natural T-cell receptor (TCR) complex by integrating with the endogenous CD3 signaling machinery. This architecture is intended to provide a more regulated and physiological T-cell activation, which may enhance the persistence and anti-tumor activity of the cells while potentially reducing the risk of severe toxicities such as cytokine release syndrome (CRS). The program is currently in the preclinical stage of development.

Other names

SLAMF7 SIR-TSLAMF-7 SIR-TSLAMF 7 SIR-TCS1-targeting Synthetic Immune Receptor T-cell therapyCS-1-targeting Synthetic Immune Receptor T-cell therapyCS 1-targeting Synthetic Immune Receptor T-cell therapy